Stephen Strickland/LinkedIn
May 4, 2025, 13:49
Stephen Strickland shared phase I SENTI-202-101 trial results at AACR 2025 – Sarah Cannon Research Institute
Sarah Cannon Research Institute shared a post on LinkedIn:
“Dr. Stephen Strickland, director of leukemia research at Sarah Cannon Research Institute, shared promising interim results from the phase I SENTI-202-101 clinical trial at AACR 2025. SENTI-202, a first-in-class CAR NK cell therapy, has shown efficacy in treating relapsed AML, with several patients achieving complete remission.
This innovative therapy leverages logic gating to target AML cells while sparing healthy ones, offering new hope for patients with high unmet medical needs.
Learn more about this pioneering research and its potential impact on cancer treatment.”
Dr. Stephen Strickland shared interim findings from the SENTI-202-101 phase I trial at AACR 2025.
The CAR NK therapy SENTI-202 showed efficacy in relapsed AML, with several complete remissions observed.
The approach uses logic gating to target cancer while preserving healthy cells.
You Can Find More Posts Featuring Sarah Cannon Research Institute on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11